Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Limtop in Actinic Keratosis
NCT01611480Phase 2Completed
- Sponsor
- Moberg Pharma AB
- Primary completion
- Jan 2013
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of imiquimod in actinic keratosis (AK), sponsored by Moberg Pharma AB. Status: completed.
02
Drugs
imiquimod
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT01611480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01611480.